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Abstract
Purpose of Review Breast MRI has been recognized as the most sensitive modality for breast cancer screening. Its use is,
however, restricted due to the high costs of the MRI scan itself, the limited availability of MRI scanners and the long reading
times. In this review, the use of shorter MRI protocols for screening is discussed.
Recent Findings Shortened scan protocols have been proposed to reduce both the actual patient handling time and the time to
evaluate the scan. So far, these “abbreviated” scan protocols have shown similar sensitivity and only marginally lower specificity
as the common scan protocols, while largely reducing scan time and time required for evaluation. To retain the dynamic
information, ultrafast dynamic breast MRI was introduced, capturing the inflow of contrast in a lesion. This comes for free in
terms of scan time. The diagnostic information from this dynamic evaluation is even stronger than the conventional curve types
and can be exceptionally helpful in the evaluation of small lesions. Since abbreviated and ultrafast MRIs are not mutually
exclusive, both techniques can be combined, yielding a screening protocol with a scan time below 5 min. However, only very
few studies evaluated these protocols in a true screening setting, and the number of detected cancers is likewise very low.
Summary Abbreviated protocols with ultrafast MRI allow shortening of breast MRI for screening while retaining excellent
sensitivity and specificity. Prospective study data are however limited and must be further substantiated.
Keywords Breast cancer . Screening . Abbreviated breastMRI . Ultrafast breastMRI
Introduction
The incidence of breast cancer is increasing worldwide. The
risk of developing breast cancer can be up to 15%, depending
on the country [1]. Current treatment options are more simple
and better tolerated if the cancers are detected at an early stage.
In addition, cancers that are detected early have a better
disease-free survival and overall survival than advanced
staged cancers [2•]. Screening for breast cancer is important
to allow early detection of cancer before the cancer is clinical-
ly found. Screeningmodality for breast cancer is mainly mam-
mography worldwide. Some Asian countries prefer breast ul-
trasound as the primary screening tool due to the relatively
small and dense breasts of women in these countries.
The mammographic screening programs have been highly
successful in reducing breast cancer-related mortality, with
reported breast cancer-related mortality reductions of up to
58% for women who actually received screening mammogra-
phy [3]. Nevertheless, mammography still fails to detect
breast cancers at an early stage in up to 30% of women, who
eventually develop distant metastasis and may die from the
disease. Mammography functions especially poor in women
who are at high risk for developing breast cancer, with a re-
ported sensitivity below 50% [4, 5]. After the discovery of
contrast-enhanced breast MRI in the mid-eighties [6, 7], it
was soon recognized that breast MRI had a considerable ad-
vantage over mammography for early breast cancer detection
with its higher sensitivity. Studies focusing on screening for
breast cancer in women with high risk revealed that there is
higher incidence of breast cancer in these high-risk women,
and as a result, fewer patients are needed to be enrolled in
these trials in order to yield significant results. The results of
these initial breast MRI screening trials in different countries
were unequivocal, despite the variation in patient populations;
the sensitivity of breast MRI is roughly double that of mam-
mography [4–5, 8–10]. In addition, breast MRI triples the
additional yield of breast US as a supplementary screening
test for women at increased risk [11]. Finally, the use of breast
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MRI as a screening tool induces a stage shift in these women
and a substantially lower risk for distant metastasis and death
(0–16% and 0–7%, respectively), when compared to historical
cohorts (27–30% and 17–25%, respectively) [12, 13].
Based upon the initial MRI screening studies, the
American Cancer Society published its recommendation in
2007 where women with a life-time risk of 20–25% or higher
are recommended to have annual breast MRI in addition to
screening mammography. This recommendation was subse-
quently adopted by the European Society for Breast Imaging
(EUSOBI) [14•, 15]. Despite the presence of these guidelines,
many national organizations do not adhere to these recom-
mendations due to issues with costs. For women with genetic
mutation, screeningMRI is cost-effective [16]; however, there
are still controversies for performing screening MRI on wom-
en at moderate or low risk. The addition of MRI to screening
mammogram in the moderate to low-risk population was felt
not to be cost-effectiveness [17].
Meanwhile, further evaluation of MRI as a screening tool
in populations at lower risk is ongoing. In a recently published
study with very liberal inclusion criteria, the supplemental
cancer detection using breast MRI in women at average risk,
with a negative screening mammogram, was 15.5 per thou-
sand in the first round, which reduced to 6.9 per thousand in
incidence rounds (nearly all only detected with MRI), fairly
equal to the mammographic detection rates in Europe, and
therefore once again showing the potential of breast MRI to
induce a stage shift in breast cancer detection [18•]. Further
prospective randomized trials in women with extremely dense
breasts and women with an increased risk based upon family
history alone are ongoing [19, 20]. Despite the very likely
highly positive results of these trials in terms of early cancer
detection and reduction of interval cancers, it can be anticipat-
ed that cost-effectiveness analysis will once again show that
breast MRI in these populations is, in general, not affordable,
thus limiting the use of an otherwise highly effective screening
tool.
For further implementation of breast MRI as a screening
tool, it is thus mandatory to reduce the costs of the examina-
tion itself, which can be most easily achieved by increasing
the throughput of patients in the MRI scanner.
Abbreviated Breast MRI
The abbreviated MRI is a shortened version of a full protocol
or standard breast MRI exam, currently performed for screen-
ing breast cancer. The concept of the abbreviated protocol is to
reduce the length of the acquisition and interpretation time of a
screening breast MRI exam to a minimum. Most researchers
focus on reducing the acquisition time of a standard breast
MRI exam which have been reported to be up to 45 min.
The criteria for defining an exam abbreviated or having a limit
on the exam time for anMRI protocol to be called abbreviated
is not yet determined. For the purpose of this paper, we will
assume that an abbreviated breast MRI protocol will have a
scan time of less than 5 min. Since patient handling times vary
between 5 to 10 min, this allows approximately four and six
breast MRI exams to be performed per hour on a scanner.
Most of the currently used breast MRI protocols consists of
at least a dynamic contrast-enhanced series [7 min], a T2-
weighted series, and possibly a diffusion weighted series last-
ing between 15 and 20 min. Longer protocols that are for
clinical care, without research sequences or non-FDA ap-
proved sequences, not needed or encouraged [15, 21].
Publications on abbreviated breast MRI to date usually in-
volve acquiring a full breast MRI protocol, with analyzed
subsets of sequences interpreted in a blinded fashion and sep-
arate from the full protocol. There are no published studies
that used only abbreviated MRI for screening currently.
In 2014, Kuhl and colleagues were the first to report the
feasibility of the simplest form of abbreviated MRI [22••].
Their version of abbreviated protocol consisted of an
unenhanced T1-weighted sequence and first contrast-
enhanced T1-weighted sequence, subtraction images with a
single maximum intensity projections (MIP) [22••]. This pro-
tocol took 3 min of scan time: 60 s delay from the start of IV
contrast injection to allow the contrast agent to flow into po-
tential lesions followed by each T1-weighted acquisitions last-
ing approximately 60 s. Interpretation was performed using
MIP from the post-contrast subtraction images (Fig. 1), and
therefore is extremely fast (reported to be less than 2 s),
allowing quick dismissal of normal cases. With this approach,
the reported overall sensitivity was 91% with MIP only and
100% with the complete subtraction series. The specificity
was 94.3%, with a negative predictive value of 99.8%. The
main advantage of using the full diagnostic protocol over ab-
breviated protocol was the ability to better characterize BI-
RADS 3 or probable benign lesions. These breast imaging-
reporting and data system (BI-RADS) 3 lesions constituted
9% of lesions detected on abbreviated MRI. While the entire
study included 606 screens, it only detected 11 cancers; there-
fore, solid conclusions about sensitivity and specificity cannot
be drawn. In a study by Mango et al. evaluating 100 breast
MRI examinations of patients with biopsy proven breast can-
cers, the reported sensitivity for interpreting the MIP images
alone was also substantially lower than when evaluating the
actual subtraction images (84–96%, vs 93–98%, over different
readers)[23]. It must be stressed that dismissing studies as
normal based upon the MIP images alone requires very good
quality MIP images without motion artifacts. Subsequent
studies evaluating different variations of abbreviated protocols
are listed in Table 1. Of note is that several abbreviated pro-
tocols do not conform to the definition of a true abbreviated
protocol given above, as the scan time is far longer than would
be acceptable for high-throughput screening.
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Fig. 1 Maximum intensity
projection of subtracted post-
contrast acquisition, clearly
showing a multifocal invasive
lobular cancer in the left breast
Table 1 Studies comparing abbreviated protocols to full diagnostic protocols: effects on sensitivity and specificity.
Author (year) Abbreviated protocol
(duration)
Number of cancers/
total cases
Sensitivity
Abbreviated
Protocol
Specificity
Abbreviated
Protocol
Sensitivity
Full diagnostic
protocol
Specificity
Full diagnostic
protocol
Kuhl 2014
[22]
T1 pre- and post-contrast (3 min) 11/606 (screening
population)
100% 94.3% 100% 93.4%
Mango 2015
[23]
Sag T1 pre- and post-contrast
(10–15 min)*
100 (cancers only) 93–98% NA 95–98% NA
Grimm 2015a
[24]
T2 FS, T1 pre- and post-contrast
(21 min)*
12/48 (enriched) 86% 52% 95% 52%
Grimm 2015a
[24]
T2 FS, T1 pre- and post-contrast +
second post-contrast
(23 min)*
12/48 (enriched) 89% 45% 95% 52%
Harvey 2016
[25]
T1 pre- and post contrast
(4.4 min)
7/568 (screening
population)
100 94% 100 96%
Heacock
2016a [26]
T1 pre- and post-contrast
(7 min)
107 (cancers only) 97.8% NA 99.4% NA
Heacock
2016a [26]
T2 FS, T1 pre- and post-contrast
(12 min)
107 (cancers only) 99.4% NA 99.4% NA
Moschetta
2016 [27]
T2 STIR, T2, T1 pre- and post-contrast
(10 min)
75/470 (clinical
population)
89% 91% 92% 92%
Chen 2017
[28]
T1 pre- and post-contrast (3 min) 16/478 (dense breast
screening)
93.8% 88.3% 100% 94.6%
Petrillo 2017
[29]
T1 pre- and post-contrast (3 min) 207/508 (clinical
population)
99.5% 75.4% 99.5% 77.1%
Chen 2017a
[30•]
T1 pre- and post-contrast (3 min) 14/356 (dense breast
screening)
92.9% 86.5% 100% 96.8%
Chen 2017a
[30•]
T1 pre- and post-contrast + DWI
(6 min)
14/356 (dense breast
screening)
100% 95% 100% 96.8%
Romeo 2017
[31]
T1 pre- and 3* post-contrast (7 min) 110/180 (lesions only) 99% 93% 97% 95%
Panigrahi
2017
[32]
T1 pre- and post-contrast (3 min) 11/678 (high-risk
screening)
81.8% 97.2% 81.8% 97.4%
* Scan time reported includes patient positioning
a reported two different abbreviated protocols in one study
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Most authors reported that the sensitivity of abbreviated
MRI is equal to the sensitivity of a full diagnostic protocol.
However, results on specificity are more heterogeneous.
While several authors did not report any deviation, many au-
thors report a small to substantial decrease in specificity when
evaluating abbreviated breast MRI [25, 27, 28, 30•, 31]. This
is in line with the initial study of Kuhl et al. and seems to be
related to the evaluation of more difficult “probably benign”
lesions and relatively small lesions. Heacock et al. reported
that lesion conspicuity in malignant breast lesions could be
increased by adding a T2-weighted sequence to the abbrevi-
ated protocol [26], whereas Chen et al. improved specificity
substantially by adding a diffusion weighted sequence [30•].
Several authors only reduce the number of post-contrast T1-
weighted acquisitions to more than one, thus still enabling
dynamic evaluation of breast lesions in the abbreviated proto-
col, which is likewise aimed at preserving the specificity as it
does not seem to have effect on sensitivity. Recently, Strahle
et al. tried to define an optimal abbreviated protocol by
assessing the diagnostic value of each of the sequences.
They obtained the best results by reducing the full protocol
to a shortened, but still dynamic T1-weighted series, inter-
leaved with a normal T2 sequence for a total acquisition time
of 7.5 min, underlining the added discriminatory value of
dynamics and to lesser extent T2 [33]. It should be noted that
their full protocol however did not include DWI. In conclu-
sion, it is evident that abbreviated MRI allows shortening of
the full diagnostic breast MRI protocol, without a significant
reduction in sensitivity. Effects on specificity are mainly lim-
ited to patients with lesions of low suspicion for malignancy
and can be improved by either preserving dynamic evaluation,
or adding T2 and DWI. However, whether the extension in
acquisition time required for improved lesion classification is
economically viable in a situation where most scans are
completely negative (i.e., in screening, especially non-high-
risk) remains debatable.
Ultrafast Breast MRI
Ultrafast breast MRI is developed to capture the inflow of
contrast in breast lesions and hence enable dynamic analysis
of contrast wash-in rather than contrast wash-out. The tech-
nique builds largely on earlier attempts to analyze the phar-
macokinetic characteristics of breast cancer vasculature,
which was shown to allow good separation between benign
and malignant breast lesions [34, 35]. The main difference
between these techniques, however, is that ultrafast breast
MRI is performed with a spatial resolution that enables mor-
phological assessment of eventual breast lesions as it meets
the international standards for diagnostic breast MRI, and can
therefore also be used for lesion detection. Like abbreviated
MRI, the term “ultrafast” is not clearly defined and sometimes
used for MRI techniques that are not exceptionally fast. In this
paper, ultrafast breast MRI is defined as T1-weighted imaging
with a temporal resolution below 6 s, and a spatial resolution
of at least 1 × 1 × 2.5 mm.
Herrmann et al. in 2011 was the first to publish, on the
approach of k-space filling, allowed construction of high-
resolution breast MRI acquisitions at a temporal resolution
of 5.7 s [36]. The commercial name of this sequence is time-
resolved angiography with stochastic trajectories (TWIST).
Hence, TWIST has become almost a synonym for ultrafast
breast MRI. Le et al. and Saranathan et al. subsequently
showed that similar results were also possible using fat-
saturated and Dixon techniques. However, these sequences
are computationally heavy and therefore require long recon-
struction times [37, 38].
In 2014, we proposed the use of ultrafast breast MRI alone
as a new screening technique for breast cancer, based upon a
study of 199 abnormalities where the wash-in characteristics
obtained with TWISTwere compared to the wash-out charac-
teristics from the same lesions obtained from regular T1-
weighted series. The ultrafast protocol obtained 20 T1-
weighted acquisition volumes at a temporal resolution of
4.3 s each, for a total duration of 102 s. Therefore, this tech-
nique is faster than any of the abbreviated protocols discussed
previously in this article. This approach shows that the max-
imum slope (MS), a heuristic dynamic parameter obtained
from the TWIST images largely outperformed the convention-
al curve types (area under the curve 0.81 vs 0.69), while still
allowing imaging at diagnostic spatial resolution. MS can be
assessed in a similar way as the curve types, where a steep
slope is indicative of malignancy; a shallow slope of a likely
benign lesion and an intermediate curve is indeterminate
[39••]. In further studies, it was subsequently shown that also
the time to enhancement relative to aortic enhancement (TTE)
is a highly discriminative and very reproducible parameter for
breast lesion characterization [40]. In simple words, lesions
that enhance within 10 s after the aorta are likely malignant;
lesions that enhance between 10 and 15 s after the aorta are
indeterminate, and lesions that enhance more than 15 s after
the aorta are likely benign. As ultrafast breast MRI allows the
generation of a series of MIP images (one for each post-
contrast time point acquired), it is possible to evaluate these
dynamic MIPS as a movie of contrast inflow. Based upon the
above, the first enhancing lesion is usually the one that de-
serves most attention. In patients with cancer, you may ob-
serve a “lightbulb” effect, as you see the cancer enhancing in
an otherwise completely black breast (Fig. 2). This effect is
also very valuable for the evaluation of breasts with nodular
background enhancement, to differentiate true lesions from
focal areas of adenosis [41]. Another approach is the assess-
ment of the time between arterial phase and venous phase in
breast lesions.When arterial supply is observed, the lesion has
a very high likelihood of being malignant. The level of
12 Curr Breast Cancer Rep (2019) 11:9–16
suspicion for malignancy is further increased when the time
from arterial phase to venous drainage is shortened, a param-
eter that is highly related to the TTE described above [42]. It is
recommended to evaluate the MIP images generated from the
last time point obtained before evaluating the other sequences.
If this MIP is of good quality and is negative for suspicious
lesions, then evaluation of the other phases or sequences is not
necessary. This observation is consistent with observations
reported on MIP reading proposed by Kuhl et al. and Mango
et al. Of note is that the excellent discriminating capacities of
MS and TTE are also valid for computer-aided diagnosis [43],
and remain valid over various types of breast cancer, including
invasive lobular cancers and ductal carcinoma in situ [44]. It is
still essential to realize that, even though with TWIST, a spa-
tial resolution is obtained of 1 × 1 × 2.5 mm; this is still lower
than in most high-resolution T1-weighted protocols where
voxels usually are below 1 mm isotropic. Consequently,
multiplane reconstruction is somewhat limited, and therefore,
morphological evaluation is not as good as with conventional
protocols in all directions. However, recent studies employing
compressed sensing with iterative reconstruction rather than
view sharing allow a substantial further reduction of the spa-
tial resolution, down to 0.8 × 0.8 × 1.6 mm, in the same
timeframe [45, 46].
Fig. 2 Maximum intensity projections from an ultrafast dynamic series
with a temporal resolution of 4.3 s. TTE is relative to the enhancement of
the descending aorta, the first volume that shows this vessel is designated
t0 (a). In b, the first volume where the lesion is visible is shown, the very
early enhancement (only 4.3 s after the aorta) make it very likely that this
lesion is malignant. In later time points, morphology becomes clear and
can be easily appreciated (c). In d, the time versus signal intensity curve
for the inflow period is presented. The very steep upslope is indicative of
malignancy
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Whether ultrafast MRI alone is good enough for breast
screening remains to be evaluated, as most published
studies to date have mainly focused on lesion classifica-
tion. Van Zelst et al., however, showed in a reader study
with TWIST only versus a full diagnostic protocol on 85
biopsied screen-detected lesions, including 31 malignan-
cies, obtained from over 3000 screening examinations,
with 115 normal cases. The average sensitivity of
TWIST only evaluation was 84%, compared to 86% for
the full diagnostic protocol, without statistical signifi-
cance. However, the relative low sensitivities show the
difficulty of the comprised case set consisting of only
screening cases. Typically, the average specificity of
TWIST only reading was, at 81%, significantly higher
than with the full diagnostic protocol at 77%, while the
average area under the curve for the two reading modes
was virtually identical [47••].
Hybrid Imaging
It is important to realize that the definitions of abbrevi-
ated and ultrafast MRI are not mutually exclusive. In
fact, ultrafast MRI alone is a form of an abbreviated
protocol with a very short acquisition time (less than
2 min). However, for the performance of ultrafast breast
MRI as a stand-alone technique, specific sequences are
required that are not uniformly available. With classic,
and far more commonly available, keyhole techniques
(i.e., turboFLASH, eThrive, etc.), it is, unfortunately,
not possible to obtain the required temporal resolution
at a diagnostically acceptable spatial resolution.
Nevertheless, even in the most basic form of an abbre-
viated protocol, the period of contrast inflow must be
observed. Kuhl et al. solved this by simply waiting
60 s before acquiring the post-contrast acquisition.
Obviously, ultrafast acquisitions (even of lower spatial
resolution) can be inserted in this waiting period without
any penalty in overall scanning time. This still allows
vary fast evaluation of the entire protocol by evaluating
the MIP image and high-resolution subtraction series, but
in the presence of lesions, substantial additional dynamic
information is present for lesion classification (it should
be noted that when the last post-contrast scan is negative,
it is not needed to evaluate all the previous phases). The
superior performance of wash-in characteristics from ul-
trafast imaging compared to standard wash-out evalua-
tion truly makes late phase acquisitions obsolete and en-
ables a huge shortening of the protocol without losing
any information. Whether or not addition of T2 or
DWI is beneficial in the screening, setting remains to
be seen.
Conclusions
Breast MRI as a screening tool is limited by the high
cost of the MRI examination itself. To enable more wide-
spread use of this highly sensitive screening technique, it
is important to reduce the price of the exam and scan-
ning time. The most practical approach to that is short-
ening the acquisition or scan time, allowing for an in-
crease in patient’s throughput and potential leading to a
reduction in price of each exam. This will likely lead to
increased patients’ acceptance and expansion of the MRI
screening population to those with intermediate risk for
the development of breast cancer, those with a positive
family history without hereditary genetic mutations, and
those women with extremely dense breasts. Abbreviated
protocols, particularly those employing (also) ultrafast
sequences, may offer the best combination. Even though
recent studies have investigated such protocols, the actu-
al number of screen detected breast cancers remains very
low and questions the value of abbreviated and ultrafast
MRI as a screening technique. Based on the current re-
sults, the sensitivity of abbreviated MRI is not signifi-
cantly different from that of a full diagnostic protocol but
better than mammography, tomosynthesis, or ultrasound.
This already underlines its potential value for supplemen-
tal evaluation of women with very dense breasts, even
when it is still somewhat unsure whether it can
completely replace the full diagnostic protocol in women
currently already screened with MRI. The specificity of
abbreviated breast MRI is lower than that of a full diag-
nostic protocol. This may lead to higher recall rate and
additional evaluations. The incorporation of ultrafast
breast MRI sequences to the abbreviated protocol may
help improve this. In conclusion, ultrafast and/or abbre-
viated MRI will most likely become the standard screen-
ing MRI technique of the future.
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